Literature DB >> 490531

Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent.

J Heeres, L J Backx, J H Mostmans, J Van Cutsem.   

Abstract

The preparation and antifungal properties of cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl-methyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine (I) are described. Ketoconazole has, at low oral doses, a high in vivi activity against vaginal candidosis in rats and against cutaneous candidosis in guinea pigs.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 490531     DOI: 10.1021/jm00194a023

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

1.  Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi.

Authors:  J A Urbina; K Lazardi; T Aguirre; M M Piras; R Piras
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 2.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

3.  Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi.

Authors:  K Lazardi; J A Urbina; W de Souza
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

Authors:  Annika Allqvist; Jun Miura; Leif Bertilsson; Rajaa A Mirghani
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 5.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

6.  Organism-dependent fungicidal activities of azoles.

Authors:  E K Manavathu; J L Cutright; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Hematogenous Candida vertebral osteomyelitis treated with ketoconazole.

Authors:  B A Dijkmans; M I Koolen; R P Mouton; T H Falke; P J van den Broek; J W van der Meer
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

8.  Distribution of oral ketoconazole to vaginal tissue.

Authors:  J J Heykants; R J Woestenborghs; M P Bisschop; J M Merkus
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

9.  In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis.

Authors:  H Van den Bossche; G Willemsens; W Cools; F Cornelissen; W F Lauwers; J M van Cutsem
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homologous locus.

Authors:  J E Parker; M Merkamm; N J Manning; D Pompon; S L Kelly; D E Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.